Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment
In a first for solid cancers, cellular immunotherapy has entered standard of care in the treatment of patients with metastatic melanoma. The infusion of autologous tumor-infiltrating T lymphocytes (TIL) is capable of mediating durable tumor regression and is now Food and Drug Administration-approved...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/1/e010207.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591926480601088 |
|---|---|
| author | Robert Brown Marco Donia Simon Turcotte George Coukos John Mullinax Brian Gastman James C Yang Michael T Lotze John B A G Haanen Inge Marie Svane Stephanie L Goff Vernon K Sondak Maartje W Rohaan Michal Besser Benjamin Creelan |
| author_facet | Robert Brown Marco Donia Simon Turcotte George Coukos John Mullinax Brian Gastman James C Yang Michael T Lotze John B A G Haanen Inge Marie Svane Stephanie L Goff Vernon K Sondak Maartje W Rohaan Michal Besser Benjamin Creelan |
| author_sort | Robert Brown |
| collection | DOAJ |
| description | In a first for solid cancers, cellular immunotherapy has entered standard of care in the treatment of patients with metastatic melanoma. The infusion of autologous tumor-infiltrating T lymphocytes (TIL) is capable of mediating durable tumor regression and is now Food and Drug Administration-approved for patients with disease refractory to immune checkpoint inhibitors. Since the advent of chimeric antigen receptor (CAR) T cells for patients with hematological malignancies, a growing network of centers capable of delivering effector T cell products to patients has developed. Administration of TIL can be layered onto that institutional framework, but there are many complex and unique aspects to TIL immunotherapy. The highly multidisciplinary clinical expertise and coordination required to successfully and safely deliver TIL to patients began within the National Cancer Institute Surgery Branch and have been subsequently adopted worldwide. The general steps, most of which require hospital inpatient resources, include a surgical procedure to harvest sufficient tumor for TIL manufacturing, admission for non-myeloablative lymphodepleting chemotherapy followed by TIL, and intravenous interleukin-2 (IL-2, aldesleukin). Here, we provide the principles, practice, and required resources underlying the efficient and safe delivery of TIL immunotherapy derived from the clinical expertise of high-volume centers around the world. This article enhances published clinical practice guidelines by providing underlying clinical rationale and data-driven examples to demystify TIL immunotherapy in order to facilitate uptake and improve patient access to this promising treatment modality in clinical and research settings. |
| format | Article |
| id | doaj-art-a61ba106bede434b97c7c2e9d6043d5a |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-a61ba106bede434b97c7c2e9d6043d5a2025-01-22T05:05:13ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-01-0113110.1136/jitc-2024-010207Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatmentRobert Brown0Marco Donia1Simon Turcotte2George Coukos3John Mullinax4Brian Gastman5James C Yang6Michael T Lotze7John B A G Haanen8Inge Marie Svane9Stephanie L Goff10Vernon K Sondak11Maartje W Rohaan12Michal Besser13Benjamin Creelan14Zai Laboratory, Chicago, Illinois, USADepartment of Oncology, National Center for Cancer Immune Therapy, Copenhagen University Hospital, Herlev, DenmarkCentre Hospitalier de l`Université de Montréal, Montréal, Quebec, CanadaUniversity Hospital of Lausanne, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, SwitzerlandH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USAIovance Biotherapeutics, Philadelphia, Pennsylvania, USASurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USAUniversity of Pittsburgh, Pittsburgh, Pennsylvania, USALeiden University Medical Center, Leiden, The NetherlandsDepartment of Oncology, National Center for Cancer Immune Therapy, Copenhagen University Hospital, Herlev, DenmarkSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USAH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USANetherlands Cancer Institute, Amsterdam, The NetherlandsDavidoff Center & Samueli Institute, Rabin Medical Center, Petach Tikva, IsraelH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USAIn a first for solid cancers, cellular immunotherapy has entered standard of care in the treatment of patients with metastatic melanoma. The infusion of autologous tumor-infiltrating T lymphocytes (TIL) is capable of mediating durable tumor regression and is now Food and Drug Administration-approved for patients with disease refractory to immune checkpoint inhibitors. Since the advent of chimeric antigen receptor (CAR) T cells for patients with hematological malignancies, a growing network of centers capable of delivering effector T cell products to patients has developed. Administration of TIL can be layered onto that institutional framework, but there are many complex and unique aspects to TIL immunotherapy. The highly multidisciplinary clinical expertise and coordination required to successfully and safely deliver TIL to patients began within the National Cancer Institute Surgery Branch and have been subsequently adopted worldwide. The general steps, most of which require hospital inpatient resources, include a surgical procedure to harvest sufficient tumor for TIL manufacturing, admission for non-myeloablative lymphodepleting chemotherapy followed by TIL, and intravenous interleukin-2 (IL-2, aldesleukin). Here, we provide the principles, practice, and required resources underlying the efficient and safe delivery of TIL immunotherapy derived from the clinical expertise of high-volume centers around the world. This article enhances published clinical practice guidelines by providing underlying clinical rationale and data-driven examples to demystify TIL immunotherapy in order to facilitate uptake and improve patient access to this promising treatment modality in clinical and research settings.https://jitc.bmj.com/content/13/1/e010207.full |
| spellingShingle | Robert Brown Marco Donia Simon Turcotte George Coukos John Mullinax Brian Gastman James C Yang Michael T Lotze John B A G Haanen Inge Marie Svane Stephanie L Goff Vernon K Sondak Maartje W Rohaan Michal Besser Benjamin Creelan Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment Journal for ImmunoTherapy of Cancer |
| title | Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment |
| title_full | Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment |
| title_fullStr | Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment |
| title_full_unstemmed | Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment |
| title_short | Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment |
| title_sort | art of til immunotherapy sitc s perspective on demystifying a complex treatment |
| url | https://jitc.bmj.com/content/13/1/e010207.full |
| work_keys_str_mv | AT robertbrown artoftilimmunotherapysitcsperspectiveondemystifyingacomplextreatment AT marcodonia artoftilimmunotherapysitcsperspectiveondemystifyingacomplextreatment AT simonturcotte artoftilimmunotherapysitcsperspectiveondemystifyingacomplextreatment AT georgecoukos artoftilimmunotherapysitcsperspectiveondemystifyingacomplextreatment AT johnmullinax artoftilimmunotherapysitcsperspectiveondemystifyingacomplextreatment AT briangastman artoftilimmunotherapysitcsperspectiveondemystifyingacomplextreatment AT jamescyang artoftilimmunotherapysitcsperspectiveondemystifyingacomplextreatment AT michaeltlotze artoftilimmunotherapysitcsperspectiveondemystifyingacomplextreatment AT johnbaghaanen artoftilimmunotherapysitcsperspectiveondemystifyingacomplextreatment AT ingemariesvane artoftilimmunotherapysitcsperspectiveondemystifyingacomplextreatment AT stephanielgoff artoftilimmunotherapysitcsperspectiveondemystifyingacomplextreatment AT vernonksondak artoftilimmunotherapysitcsperspectiveondemystifyingacomplextreatment AT maartjewrohaan artoftilimmunotherapysitcsperspectiveondemystifyingacomplextreatment AT michalbesser artoftilimmunotherapysitcsperspectiveondemystifyingacomplextreatment AT benjamincreelan artoftilimmunotherapysitcsperspectiveondemystifyingacomplextreatment |